SeekingAlpha · Sep 20, 2026
GH Research: 'Buy' GH001 TRD Advancement Presses On And Expansion Opportunities
Initiate coverage on GH Research: Buy rating as FDA hold lifts for GH001 TRD, Phase 3 in 2026. Click for more on GHRS stock.
GH
NASDAQ · GHRS
GH Research PLC
Healthcare · Biotechnology
$21.52
Down-$0.65 (-2.93%)
Updated Oct 7, 2026, 7:05 AM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 857.25M
- P/E ratio
- -20.9
- Dividend yield
- 0.00%
- 52-week range
- $12.77 – $31.44
- Volume
- 495.43K
- Avg. volume
- 321.53K
Price performance · GHRS
GHRS price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
GHRS closed at $21.52 after 21 trading sessions, down 22.56% for the selected period.
- Last close
- $21.52
- Period change
- -22.56%
- Period low
- $21.52
- Period high
- $28.72
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $22.23 | $22.27 | $21.21 | $21.52 | 495.43K |
| Oct 5, 2026 | $23.00 | $23.00 | $21.862 | $22.17 | 206.96K |
| Oct 2, 2026 | $23.05 | $23.12 | $22.36 | $22.94 | 230.11K |
| Oct 1, 2026 | $23.31 | $23.90 | $22.53 | $22.86 | 255.12K |
| Sep 30, 2026 | $24.92 | $24.92 | $23.13 | $23.48 | 384.73K |
| Sep 29, 2026 | $23.39 | $24.99 | $23.12 | $24.67 | 1.13M |
| Sep 28, 2026 | $23.48 | $23.675 | $22.89 | $23.42 | 609.73K |
| Sep 25, 2026 | $24.48 | $24.55 | $23.49 | $23.84 | 179.99K |
| Sep 24, 2026 | $26.10 | $26.10 | $23.43 | $24.45 | 418.31K |
| Sep 23, 2026 | $28.13 | $28.13 | $25.67 | $25.96 | 178.83K |
| Sep 22, 2026 | $28.02 | $28.45 | $27.61 | $27.86 | 101.62K |
| Sep 21, 2026 | $28.48 | $28.50 | $27.76 | $27.93 | 131.17K |
| Sep 18, 2026 | $28.87 | $29.15 | $28.00 | $28.26 | 132.83K |
| Sep 17, 2026 | $28.11 | $29.165 | $27.755 | $28.72 | 501.57K |
| Sep 16, 2026 | $27.63 | $28.07 | $27.22 | $27.75 | 152.95K |
| Sep 15, 2026 | $27.63 | $27.83 | $26.52 | $27.55 | 140.27K |
| Sep 14, 2026 | $27.20 | $28.62 | $27.0282 | $27.89 | 157.58K |
| Sep 11, 2026 | $27.57 | $28.11 | $27.01 | $27.20 | 159.25K |
| Sep 10, 2026 | $27.242 | $27.605 | $26.875 | $27.28 | 128.8K |
| Sep 9, 2026 | $27.77 | $27.92 | $26.46 | $27.56 | 336.85K |
| Sep 8, 2026 | $27.98 | $28.33 | $27.21 | $27.79 | 221.03K |
Latest GHRS news
The latest Smart Investors Daily articles mentioning GHRS.
Stock researchCompany · Overview
Company
Market Activity
Research & News
GHRS research
Overview
Company profile and research snapshot.
Company profile
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $27.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | Guggenheim | Buy | — |
| Aug 7, 2026 | Cantor Fitzgerald | Overweight | — |
| Aug 6, 2026 | Needham | Buy | — |
| Jul 27, 2026 | Wells Fargo | Overweight | — |
| May 19, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 7, 2026
Guggenheim Maintains Buy on GH Research, Raises Price Target to $40
Guggenheim analyst Eddie Hickman maintains GH Research (NASDAQ:GHRS) with a Buy and raises the price target from $34 to $40.
Benzinga · Aug 7, 2026
Cantor Fitzgerald Maintains Overweight on GH Research, Raises Price Target to $40
Cantor Fitzgerald analyst Charles Duncan maintains GH Research (NASDAQ:GHRS) with a Overweight and raises the price target from $35 to $40.
Benzinga · Aug 6, 2026
Needham Maintains Buy on GH Research, Raises Price Target to $39
Needham analyst Ami Fadia maintains GH Research (NASDAQ:GHRS) with a Buy and raises the price target from $32 to $39.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
